EMA Approves Expansion of Moleculin Biotech’s Leukemia Trial, Boosting Annamycin’s Reach in Europe
Moleculin Biotech Inc. has received approval from the European Medicines Agency to expand its Phase 3 clinical trial for Annamycin, a potential treatment for relapsed or refractory acute myeloid leukemia.
2 minutes to read